SKA2P1: A Protein Involved in Cell Division and Cancer Development

Target Name: SKA2P1

NCBI ID: G729012

SKA2P1

Other Name(s): Em:AC006313.1 | SKA2L | FAM33B | spindle and kinetochore associated complex subunit 2 pseudogene 1 | Spindle and kinetochore associated complex subunit 2 pseudogene 1

SKA2P1: A Protein Involved in Cell Division and Cancer Development

SKA2P1 (Em:AC006313.1) is a protein that is expressed in various tissues of the body, including the brain, lungs, and heart. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer.

SKA2P1 has been identified as a potential drug target in a variety of settings. Its role in cell division and the cell cycle has made it a focus for researchers looking for new treatments for cancer. Additionally, its expression has been linked to a number of diseases, including neurodegenerative disorders, and researchers are exploring its potential as a potential drug target for these conditions as well.

One of the key challenges in studying SKA2P1 is its complex structure. SKA2P1 is a transmembrane protein that is expressed in the cytoplasm of cells, and its function is not well understood. To study its effects, researchers have used a variety of techniques, including cell-based assays, biochemical assays, and animal models.

One of the ways that SKA2P1 has been studied is through cell-based assays. These experiments have shown that SKA2P1 plays a role in regulating the cell cycle, and that it is involved in the development of many diseases. For example, researchers have found that SKA2P1 is involved in the development of cancer, and that it promotes the growth and survival of cancer cells.

Another way that SKA2P1 has been studied is through biochemical assays. These experiments have shown that SKA2P1 is involved in a number of different cellular processes, including the production of proteins, DNA replication, and cell division. For example, researchers have found that SKA2P1 is involved in the production of the protein cyclin D1, which is important for cell division.

In addition to its role in the cell cycle, SKA2P1 has also been linked to a number of diseases. Its expression has been linked to a variety of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Additionally, SKA2P1 has been linked to the development of heart disease, and researchers are exploring its potential as a potential drug target for these conditions.

One of the challenges in studying SKA2P1 is its complex structure.SKA2P1 is a transmembrane protein that is expressed in the cytoplasm of cells, and its function is not well understood. To study its effects, researchers have used a variety of techniques, including cell-based assays, biochemical assays, and animal models.

In conclusion, SKA2P1 is a protein that is expressed in various tissues of the body and is involved in the development and progression of many diseases, including cancer. Its role in cell division and the cell cycle makes it a focus for researchers looking for new treatments for these conditions. Additionally, its expression has been linked to a number of neurodegenerative disorders, and researchers are exploring its potential as a potential drug target for these conditions as well. Further studies are needed to fully understand its effects and its potential as a drug.

Protein Name: Spindle And Kinetochore Associated Complex Subunit 2 Pseudogene 1

The "SKA2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SKA2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets